Conclusions
In a contemporary cohort of children from Florida with HM, we found that B children had an increased likelihood of receiving an HLA-mismatched donor HCT, and in particular a mismatched related donor transplant. HLA-matching significantly affected 2-year survival among W but not among B HCT recipients. Despite increased use of mismatched donors, overall survival, incidence of GVHD and causes of death did not differ between W and B children receiving HCT for hematologic malignancies.